Study of Olaparib in Combination With Pembrolizumab in the Treatment of Homologous Recombination Repair Mutation and/or Homologous Recombination Deficiency -Positive Advanced Cancer
The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable)